RALEIGH, N.C., Feb. 27, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host "Treatment of Pain and Opioid Dependence with Buprenorphine" for investors and analysts on Thursday, March 7, 2013 at 12:00 pm, in New York City. This event will include insightful discussion from medical experts with extensive experience in the management of chronic pain and opioid dependence using various formulations of buprenorphine, including BDSI's BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX).
The presentations from physician experts include:
All three experts will be on the panel and have participated in either the BEMA Buprenorphine chronic pain or BNX opioid addiction programs and will be able to offer their perspectives based on "hands on" experiences.
Management presentations will focus on the clinical programs and the market opportunity for BEMA Buprenorphine for the treatment of moderate to severe chronic pain, and BNX for the management of opioid dependence.
BDSI and its commercial partner, Endo Health Solutions, continue to enroll patients in the ongoing Phase 3 clinical trials for BEMA Buprenorphine. Both studies are anticipated to be completed by late 2013 or early 2014. Additionally, the Company expects to file the New Drug Application (NDA) for BNX with the U.S. Food and Drug Administration (FDA) in mid-2013.
Institutional investors and analysts may register to attend by contacting Brian Korb (firstname.lastname@example.org). Interested parties may access the live presentation on the BioDelivery Sciences website at www.bdsi.com. A webcast will also be available for 30 days following the event.
About BioDelivery Sciences International
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions. Additionally, BDSI is developing a high dose formulation of buprenorphine in combination with naloxone (BNX) for the treatment of opioid dependence. Both BEMA Buprenorphine and BNX are in Phase 3 clinical development. BDSI's headquarters is located in Raleigh, North Carolina. For more information visit www.bdsi.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentations discussed herein and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy. Actual results (including, without limitation, the anticipated timeframes relating to the development of BEMA Buprenorphine and BNX) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences logo is a trademark owned by BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.
© BioDelivery Sciences International, Inc. All rights reserved.
|SOURCE BioDelivery Sciences International, Inc.|
Copyright©2012 PR Newswire.
All rights reserved